October 22, 2014

The pharmaceutical industry has committed considerable resources to developing both vaccines and treatments to address the current Ebola crisis.

 

October 22, 2014

Adult millennials ages 18 years to 32 years worry about their health and access to health care as much as their baby boomer elders.

October 21, 2014

Boehringer Ingelheim Pharmaceuticals on Monday announced that Ofev (nintedanib) capsules are now available in the United States. Ofev was approved by the Food and Drug Administration on Oct. 15 to treat idiopathic pulmonary fibrosis.

October 21, 2014

H.D. Smith on Monday appointed Rob Meriweather as VP sales.

 

October 21, 2014

McKesson and Health Mart on Monday featured solutions designed to help community pharmacies deliver better patient care and sustain growth.

 

October 21, 2014

A team of scientists, led by researchers at the Wistar Institute, has identified a possible explanation for why middle-aged adults were hit especially hard by the H1N1 influenza virus during the 2013-14 influenza season.

 

October 20, 2014

Cardinal Health on Monday announced that independent pharmacies can now take advantage of opportunities to co-brand with the Medicine Shoppe and Medicap Pharmacy franchising systems.

October 17, 2014

Healthentic, an analytics company that identifies health savings for employers, found the overall vaccination rate of employees was only 10%.

October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 16, 2014

The Food and Drug Administration has granted approval to Esbriet (pirfenidone), as well as Ofev (nintedanib), to treat idiopathic pulmonary fibrosis — a condition in which the lungs scar over time.

October 16, 2014

 Big Belli on Thursday announced the December 2014 premiere of a documentary called “40 Weeks.” 

October 15, 2014

 H. D. Smith was recently announced as a finalist of the 2014 Illinois Family Business of the Year Awards in the Large Family Business of the Year and the Community Service categories.

October 15, 2014

Mission Pharmacal Co. on Tuesday announced that the U.S. District Court for the Western District of Texas has issued a consent judgment confirming the validity of its dual-iron patent.

October 15, 2014

Sanofi US announced Wednesday the findings of a new survey that reveals striking differences in opinion among various age groups about diabetes and available treatment options.

October 14, 2014

Healthgrades on Monday announced the launch of its new Cold and Flu Center at http://www.healthgrades.com/right-care/cold-and-flu/.

October 14, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday launched AccessBetterCoverage.org.

 

October 10, 2014

The Food and Drug Administration on Friday approved Akynzeo (netupitant and palonosetron) for the treatment of nausea and vomiting in patients who are undergoing cancer chemotherapy.

October 10, 2014

The Food and Drug Administration on Friday approved Gilead's Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus genotype 1 infection.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 9, 2014

Endo International and Auxilium Pharmaceuticals on Thursday announced that they have entered into a definitive agreement.

October 9, 2014

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.

October 9, 2014

Salix Pharmaceuticals on Thursday announced that the Food and Drug Administration granted final approval for the company's Uceris (budesonide) rectal foam for patients with mild-to-moderate distal ulcerative colitis. 

October 8, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday released a new report highlighting the number of investigational cancer medicines that did not succeed in clinical trials. 

October 8, 2014

Boehringer Ingelheim on Wednesday announced that its Striverdi Respimat (olodaterol) inhalation spray in 5-mcg dosage strength is now available by prescription in pharmacies across the United States.